BeiGene Newsroom

Bernstein Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207

Futu NewsNov 30 01:32

Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)

TipRanksNov 28 20:23

Research Reports Prospecting丨China Merchants Securities: First gives Beigene a "strong buy" rating, bullish on the rapid increase in sales of products such as Zejula in the short to medium term.

Gelonghui FinanceNov 22 14:18

BeiGene (688235): Deeply understanding the field of disease and entering the global competitive stage

china merchantsNov 21 00:00

Major Bank Rating | bocom intl: Raises beigene target price to 159 HKD, catalysts are about to be densely launched.

Gelonghui FinanceNov 18 15:57

Research reports highlight | Soochow Securities: Beigene's growth certainty is relatively high, maintaining a "buy" rating.

Gelonghui FinanceNov 18 15:47

BeiGe-U (688235): Overseas sales lead in rapid volume hematoma industry

soochowNov 17 19:22

bocom intl: raised beigene (06160) target price to 159 Hong Kong dollars. Q3 product sales and operation continue to improve.

Zhitong FinanceNov 15 09:31

[Brokerage Focus] Bocom Intl raises the target price of Beigene (06160) and points out that product sales and operation continue to improve in Q3 2024.

Golden Guard Financial NewsNov 15 09:10

BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207

Futu NewsNov 14 19:31

BeiGene's Strong Financial Performance and Growth Potential Justifies Buy Rating

TipRanksNov 14 15:39

Research reports Focus丨Tianfeng: Beigene Q3 adjusted operating profit reached $65.6 million, maintaining a "buy" rating

Gelonghui FinanceNov 14 14:28

[Brokerage Focus] Guoyuan International cuts Beigene (06160) target price to HK$153, pointing to 3Q24 performance slightly below expectations.

Jingwu Financial NewsNov 14 13:45

BEIGENE LTD(6160.HK):3Q24 REVENUE MILESTONE OF US$1BN+ WITH ROBUST PIPELINE PROGRESS DESPITE SIGNS OF MARKET MODERATION

Nov 14 11:52

BeiGene (688235): Continuous profit core under NON-GAAP caliber, excellent clinical data in the research pipeline

tianfengNov 14 07:17

BeiGene Is Maintained at Buy by TD Cowen

Dow JonesNov 14 02:12

BeiGene Analyst Ratings

BenzingaNov 14 02:02

BeiGene (6160.HK): 3Q24 product sales and operations continue to improve, and the catalyst is about to be intensively implemented to raise target prices

bocom intlNov 14 00:00

TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260

Futu NewsNov 13 21:32

BeiGene (688235): Product revenue continued to grow high in the third quarter, and net cash inflows from operating activities were corrected

swhy researchNov 13 20:16